<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00693589</url>
  </required_header>
  <id_info>
    <org_study_id>KEK-Nr. 115/03</org_study_id>
    <nct_id>NCT00693589</nct_id>
  </id_info>
  <brief_title>Effect of Homocysteine-Lowering Therapy With Folic Acid, Vitamin B12, and Vitamin B6 on Endothelium-Dependent Vasodilatation of Forearm Resistance Vessels in Patients With Coronary Heart Disease</brief_title>
  <official_title>Effect of Homocysteine-Lowering Therapy With Folic Acid, Vitamin B12, and Vitamin B6 on Endothelium-Dependent Vasodilatation of Forearm Resistance Vessels in Patients With Coronary Heart Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endothelial dysfunction is an early marker of atherosclerosis and is found in patients (pts)
      with coronary (CAD) and peripheral artery disease (PAD). Statin-therapy has been shown to
      improve endothelial function in pts with CAD or PAD by reducing LDL-cholesterol and
      inflammatory markers. B-group vitamin-supplements have variable been reported to have
      positive or neutral effects on endothelial function. Therefore, we want to compare the effect
      of rosuvastatin and B-group vitamin supplementation on endothelial function of the forearm
      resistance vessels in pts with cardiovascular disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: 36 pts with CAD or PAD are randomly assigned to either rosuvastatin 10mg/d or
      vitamin supplementation with folic acid 1mg, vitamin B12 0.4mg and B6 10mg/d for 6 weeks in a
      double-blinded design. After 6 weeks all pts receive rosuvastatin and vitamin supplementation
      in combination for additional 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">February 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Flow mediated dilatation (FMD)</measure>
    <time_frame>after 6 weeks of randomized treatment and after 6 weeks of combined treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in biochemistry parameters</measure>
    <time_frame>after 6 weeks of randomized treatment and after 6 weeks of combined treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Cardiovascular Disease</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>R</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rosuvastatin treatment for 6 weeks and after that combined treatment with rosuvastatin and vitamin supplementation for additional 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>V</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vitamin supplementation with folic acid, vitamin B12 and B6 for 6 weeks and after that combined treatment with vitamin supplementation and rosuvastatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>folic acid, vitamin B12 and B6 and rosuvastatin</intervention_name>
    <description>Vitamin supplementation with folic acid 1mg/d, vitamin B12 0.4mg/d and B6 10mg/d po for 6 weeks alone vs. rosuvastatin 10mg/d for 6 weeks alone and thereafter combined treatment for 6 weeks</description>
    <arm_group_label>R</arm_group_label>
    <arm_group_label>V</arm_group_label>
    <other_name>Crestor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CAD or PAD (&gt;50% luminal stenosis), previous myocardial infarction or bypass surgery
             &gt;3 month ago

          -  history of percutaneous coronary intervention (PTCA or stenting)

          -  confirmed consent

        Exclusion Criteria:

          -  myocardial infarction or acute coronary syndrome or bypass surgery &lt;3 month ago

          -  ongoing treatment with statins

          -  ongoing vitamin supplementation with folic acid and B vitamins

          -  &lt;18 years

          -  active smokers

          -  uncontrolled arterial hypertension

          -  renal insufficiency

          -  atrial fibrillation

          -  liver disease

          -  NYHA class &gt;2

          -  familial hypercholesterolemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kerstin Wustmann, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cardiology, Inselspital, University hospital Bern</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yves Allemann, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cardiology, Inselspital, University hospital Bern</affiliation>
  </overall_official>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2008</study_first_submitted>
  <study_first_submitted_qc>June 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2008</study_first_posted>
  <last_update_submitted>June 6, 2008</last_update_submitted>
  <last_update_submitted_qc>June 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>Allemann, Y., MD</name_title>
    <organization>Cardiology, Inselspital Berne</organization>
  </responsible_party>
  <keyword>endothelial function</keyword>
  <keyword>flow mediated dilatation</keyword>
  <keyword>rosuvastatin</keyword>
  <keyword>folic acid</keyword>
  <keyword>B vitamins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
    <mesh_term>Vitamin B 6</mesh_term>
    <mesh_term>Pyridoxal</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

